EntryPoint Capital’s Neurogene NGNE Stock Holding History

EntryPoint Capital’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,666	Closed	-$148K	–	741
2025 Q1	$148K	Buy	+12,666	New	+$220K	0.07%	587

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

EntryPoint Capital's NGNE Position: Q2 2025 in Review

EntryPoint Capital sold out of Neurogene (NGNE) in Q2 2025, closing a stake of 12,666 shares — an estimated $148K sold.

EntryPoint Capital first reported a position in NGNE in Q1 2025 and held it in 1 quarter. The position peaked at $148K in Q1 2025. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2025.

EntryPoint Capital reported no remaining Neurogene position as of Q2 2025 after selling out during the quarter.
EntryPoint Capital sold 12,666 Neurogene shares in Q2 2025, an estimated $148K.
EntryPoint Capital first reported a position in Neurogene in Q1 2025 and held it in 1 quarter.
EntryPoint Capital's Neurogene position peaked at $148K in Q1 2025.
82 funds tracked by Wall St. Rank held Neurogene as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.